Yue Xiang Yue Health Submits IPO Application in September 2025
Healthgen Biotech
Research and Product Developer of Plant-derived Recombinant Protein Expression Technology
Atom Therapeutics
Innovative Drug Developer
Genocury
Developer of Novel Therapies in Oncology Genetics and Cell Therapy
SMAVEW
SMAVEW
Click to follow? | Focus on Global Biomedical Investment
In the first half of 2025, the National Medical Products Administration (NMPA) approved a total of 53 new chemical drug products, representing a 43% increase compared to the same period in 2024, including 27 innovative chemical drugs.
This impressive report card not only reflects the strength of China's pharmaceutical innovation but also serves as the best testament to those with foresight in strategic planning. Amid this powerful wave of innovation, Everfront Capital and the pharmaceutical companies it collaborates with are making a significant contribution to this remarkable achievement through their outstanding performance.
01
Progress of Listed Companies and Financing
Healthgen Biotech
· Officially launch the issuance work
Healthgen Biotech
· Officially launch the issuance work
On the evening of September 22, Healthgen Biotech disclosed the prospectus, issuance arrangements, and preliminary price inquiry announcement on the Shanghai Stock Exchange website, officially launching its issuance process.
Atom Therapeutics
· Atom Therapeutics Files for Hong Kong IPO, Post-Money Valuation of RMB 3.05 Billion in Last Round
Atom Therapeutics
· Atom Therapeutics Files for Hong Kong IPO, Post-Money Valuation of RMB 3.05 Billion in Last Round
On September 15, Atom Therapeutics' Hong Kong IPO application was accepted, and the prospectus was officially published. Since its establishment, Atom Therapeutics has undergone multiple rounds of financing, completing a D-round financing of 552.2 million yuan in 2023-2025, with a post-investment valuation of 3.0522 billion yuan.
Jiyin Biotech
· Jiyin Biotech Completes A+ Round Financing
Recently, Shenzhen Jiyin Biotechnology Co., Ltd., which focuses on the development of universal cell therapies,Completed A+ round of financing. As the core technology continues to be validated and mature, Jiin Biotech is committed to expanding universal cell therapy into multiple treatment areas such as cancer and autoimmune diseases, meeting diverse clinical needs and effectively promoting the democratization of cellular immunotherapy.
SMAVEW
· SMAVEW Completes Pre-A+ Round Financing
Recently, Wuhan SMAVEW Biotechnology Co., Ltd. completed its Pre-A+ round of financing. The funds from this round will mainly be used for product development, market promotion, and team expansion, further solidifying the company's leading position in the high-end biomedical imaging field.
Jiyin Biotech
· Jiyin Biotech Completes A+ Round Financing
Recently, Shenzhen Jiyin Biotechnology Co., Ltd., which focuses on the development of universal cell therapies,Completed A+ round of financing. As the core technology continues to be validated and mature, Jiin Biotech is committed to expanding universal cell therapy into multiple treatment areas such as cancer and autoimmune diseases, meeting diverse clinical needs and effectively promoting the democratization of cellular immunotherapy.
SMAVEW
· SMAVEW Completes Pre-A+ Round Financing
SMAVEW
· SMAVEW Completes Pre-A+ Round Financing
Recently, Wuhan SMAVEW Biotechnology Co., Ltd. completed its Pre-A+ round of financing. The funds from this round will mainly be used for product development, market promotion, and team expansion, further solidifying the company's leading position in the high-end biomedical imaging field.
Xuanzhu Biotech
· Xuanzhu Biotech IPO Receives Filing Approval from China Securities Regulatory Commission
Xuanzhu Biotech
· Xuanzhu Biotech IPO Receives Filing Approval from China Securities Regulatory Commission
Recently, the International Cooperation Department of the China Securities Regulatory Commission issued a filing notice (Guo He Han [2025] No. 1470) regarding the overseas issuance and listing of Xuanzhu Biotech Co., Ltd. and the "full circulation" of its unlisted domestic shares. According to the filing notice, Xuanzhu Biotech plans to issue no more than 77,433,500 overseas-listed ordinary shares and list them on the Hong Kong Stock Exchange, while 17 shareholders intend to convert a total of 93,368,496 unlisted domestic shares into overseas-listed shares.
02
Clinical and Commercial Dynamics of Invested Companies
Healthgen Biotech
· Innovative Forum on Breakthroughs and Integrated Development of Recombinant Protein Technology Successfully Concludes
On the morning of September 5, the Innovative Forum on Breakthroughs and Integrated Development of Recombinant Protein Technology and the Launch Ceremony of Aofumin® - Recombinant Human Albumin Injection (Rice) were successfully held in Wuhan. This forum was jointly organized by the Chinese Society of Biotechnology and Wuhan Healthgen Biotechnology Corp.
Healthgen Biotech
· Innovative Forum on Breakthroughs and Integrated Development of Recombinant Protein Technology Successfully Concludes
Healthgen Biotech
· Innovative Forum on Breakthroughs and Integrated Development of Recombinant Protein Technology Successfully Concludes
On the morning of September 5, the Innovative Forum on Breakthroughs and Integrated Development of Recombinant Protein Technology and the Launch Ceremony of Aofumin® - Recombinant Human Albumin Injection (Rice) were successfully held in Wuhan. This forum was jointly organized by the Chinese Society of Biotechnology and Wuhan Healthgen Biotechnology Corp.
Baiyinno Bio
· Bioinno NK Cell Expansion Kit: Unlocking Higher Efficiency and Purity in Cell Culture Solutions
Baiyinno Bio
· Bioinno NK Cell Expansion Kit: Unlocking Higher Efficiency and Purity in Cell Culture Solutions
Recently, Bioinno Biotech launched a professional NK cell expansion kit, breaking through traditional technical bottlenecks to ensure efficient NK cell expansion, providing reliable support for cell therapy and helping this "natural immune guardian" benefit more patients.
· Debut at BPI US 2025 Conference
September 15-18, the world's largest bioprocessing event ——BioProcess International Conference & Exhibition(abbreviation: BPI) in Boston, USAConvened successfully.Bioinno CEO Dr. Zhao Xiaojian and COO Dr. Scott M Wheelwright jointly attended the exhibition. At the exhibition site, Bioinno set up an exclusive booth to comprehensively showcase the company'sSerum-free media (MSC, PSC series), GMP-grade stem cell exosomes and other core products, as well as one-stop R&D services for biopharmaceutical companies。
· Debut at BioCMC2025: Exploring the Frontiers of Biopharmaceutical Industrialization
On September 4-5, BioCMC2025, the 9th Bestbio CMC Technology Innovation Conference, will be held in Suzhou. At the exhibition site, Biokinom Biotech has set up an exclusive booth to comprehensively showcase its core products, including serum-free culture media (MSC, PSC series) and GMP-grade stem cell exosomes, as well as one-stop R&D services for biopharmaceutical companies.
· Debut at BioCMC2025: Exploring the Frontiers of Biopharmaceutical Industrialization
On September 4-5, BioCMC2025, the 9th Bestbio CMC Technology Innovation Conference, will be held in Suzhou. At the exhibition site, Biokinom Biotech has set up an exclusive booth to comprehensively showcase its core products, including serum-free culture media (MSC, PSC series) and GMP-grade stem cell exosomes, as well as one-stop R&D services for biopharmaceutical companies.
Xuanyu Medical
· Multiple Hospitals Adopt XuanYu Medical Technology for Surgeries
Recently, the Department of Cardiology at Tongling People's Hospital,Cardiovascular MedicineSuccessfully applied RhythPulse® pulsed field ablation catheter to perform surgery on patients with atrial fibrillation.
The Cardiology Department of the Second Affiliated Hospital of Harbin Medical University Successfully Completes One of the First Batch of RhythPulse®-PFA Ablation Surgeries in China, Produced by Xuan Yu Medical.
The Cardiology Department of Beijing Ditan Hospital, Capital Medical University Completes Beijing’s First Case of RhythPulse®-PFA Atrial Fibrillation Ablation Produced in China.
Zhujiang Hospital of Southern Medical University Successfully Applies RhythPulse® Pulsed Field Ablation System to Perform Pulsed Field Ablation Surgery on a Patient with Atrial Fibrillation.
Wuhan Asia Heart General Hospital Performs Pulsed Field Ablation Surgery on an Atrial Fibrillation Patient Using RHYTHPULSE® Pulsed Field Ablation Catheter from XuanYu Medical.
Beijing Anzhen Hospital, Capital Medical University Successfully Performs Pulsed Field Ablation for a Patient with Paroxysmal Atrial Fibrillation, Completing Bilateral Pulmonary Vein Isolation.
The Cardiology Department of Tianjin Medical University General Hospital successfully applied the RhythPulse® PFA Pulsed Field Ablation System developed by XuanYu Medical to perform pulsed field ablation under deep sedation for two elderly patients with a history of cerebral infarction and paroxysmal atrial fibrillation.
Professor Wu Mingxing's team from Xiangtan Central Hospital, led by Director Li Wenbin, successfully performed pulsed electric field ablation surgery on a patient with atrial flutter using the RhythPulse® pulsed electric field ablation catheter.
Taizhou Central Hospital's Cardiology Department Used RhythPulse® Pulsed Field Ablation Catheter to Perform Pulsed Field Ablation Surgery for a Patient with Atrial Fibrillation.
Dr. Chaofeng Chen's team from Huai'an Hospital in Huai'an City successfully completed three cases of RhythPulse®-PFA pulsed field ablation surgeries using domestically produced XuanYu Medical equipment.
The Cardiology Department of the Second Affiliated Hospital of Wenzhou Medical University used the RhythPulse® Pulsed Field Ablation Catheter to perform a pulsed field ablation procedure for atrial fibrillation on a patient with atrial fibrillation.
Xuanyu Medical
· Multiple Hospitals Adopt XuanYu Medical Technology for Surgeries
Recently, the Department of Cardiology at Tongling People's Hospital,Cardiovascular MedicineSuccessfully applied RhythPulse® pulsed field ablation catheter to perform surgery on patients with atrial fibrillation.
The Cardiology Department of the Second Affiliated Hospital of Harbin Medical University Successfully Completes One of the First Batch of RhythPulse®-PFA Ablation Surgeries in China, Produced by Xuan Yu Medical.
The Cardiology Department of Beijing Ditan Hospital, Capital Medical University Completes Beijing’s First Case of RhythPulse®-PFA Atrial Fibrillation Ablation Produced in China.
Zhujiang Hospital of Southern Medical University Successfully Applies RhythPulse® Pulsed Field Ablation System to Perform Pulsed Field Ablation Surgery on a Patient with Atrial Fibrillation.
Wuhan Asia Heart General Hospital Performs Pulsed Field Ablation Surgery on an Atrial Fibrillation Patient Using RHYTHPULSE® Pulsed Field Ablation Catheter from XuanYu Medical.
Beijing Anzhen Hospital, Capital Medical University Successfully Performs Pulsed Field Ablation for a Patient with Paroxysmal Atrial Fibrillation, Completing Bilateral Pulmonary Vein Isolation.
The Cardiology Department of Tianjin Medical University General Hospital successfully applied the RhythPulse® PFA Pulsed Field Ablation System developed by XuanYu Medical to perform pulsed field ablation under deep sedation for two elderly patients with a history of cerebral infarction and paroxysmal atrial fibrillation.
Professor Wu Mingxing's team from Xiangtan Central Hospital, led by Director Li Wenbin, successfully performed pulsed electric field ablation surgery on a patient with atrial flutter using the RhythPulse® pulsed electric field ablation catheter.
Taizhou Central Hospital's Cardiology Department Used RhythPulse® Pulsed Field Ablation Catheter to Perform Pulsed Field Ablation Surgery for a Patient with Atrial Fibrillation.
Dr. Chaofeng Chen's team from Huai'an Hospital in Huai'an City successfully completed three cases of RhythPulse®-PFA pulsed field ablation surgeries using domestically produced XuanYu Medical equipment.
The Cardiology Department of the Second Affiliated Hospital of Wenzhou Medical University used the RhythPulse® Pulsed Field Ablation Catheter to perform a pulsed field ablation procedure for atrial fibrillation on a patient with atrial fibrillation.
TingSheng Technology
· Wuhan Wuchang Hospital Completes Surgery Under Tingzun ICE Guidance
TingSheng Technology
· Wuhan Wuchang Hospital Completes Surgery Under Tingzun ICE Guidance
Recently, Professor Wang Liyue's team from Wuchang Hospital in Wuhan successfully completed a left atrial appendage closure surgery on a patient with a high risk of stroke after atrial fibrillation radiofrequency ablation, guided by the first domestically produced intracardiac ultrasound system, TINGSN Sonic Eyes 10.
ScienCell Biotech
· Significant Progress Made in the Field of Osteoarthritis Treatment
ScienCell Biotech
· Significant Progress Made in the Field of Osteoarthritis Treatment
Recently, Dr. Zhe Sun, co-founder and Chief Technology Officer of Corent Biomedical Technology (Hangzhou) Co., Ltd., collaborated with Professor Lawrence J. Bonassar and Professor David Putnam from Cornell University to publish a research paper titled "Synthetic Lubrication of Bone Interfaces for Late-Stage Osteoarthritis Treatment" in the authoritative journal *Langmuir* in the field of materials science. This study reports for the first time a diblock copolymer capable of effectively lubricating subchondral bone interfaces, offering a potential non-surgical treatment option for patients with late-stage osteoarthritis (OA).
Weimai Medical
· First of its kind! "Three-in-One" Stent Imaging, 10ms Reconstruction, 99% Recognition Rate Revolutionizes Tradition
Weimai Medical
· First of its kind! "Three-in-One" Stent Imaging, 10ms Reconstruction, 99% Recognition Rate Revolutionizes Tradition
Recently,Weimai MedicalWith its self-developed AI algorithms and non-rigid registration technology, the seamless integration of multi-modal data in underlying algorithms and system architecture has been achieved, making it the world's first company to offer a "full-process stent visualization solution." The "three-in-one" stent precision display allows doctors to observe the stent status from all angles and perspectives during surgery, flexibly switch modes according to the needs of different stages, covering the entire cycle from preoperative planning to postoperative follow-up. This greatly simplifies operational procedures, improves surgical efficiency, significantly broadens clinical application scenarios, and truly achieves "one device, comprehensive solutions." It not only pushes the clinical value of stent precision display to new heights but also establishes Weimai Medical’s leading position in the field of stent precision visualization.
· Weimai Medical Debuts at 2025 CIFTIS, Interventional Robot Showcases New Quality Productivity of "Made in China"
· Weimai Medical Debuts at 2025 CIFTIS, Interventional Robot Showcases New Quality Productivity of "Made in China"
Recently, the 2025 China International Fair for Trade in Services (CIFTIS) grandly opened at Shougang Park in Beijing. At this event, representing the highest national standards, Weimai Medical participated in multiple CIFTIS showcases — exhibiting its interventional robot in the core area, with senior representatives delivering keynote speeches and signing on-site agreements for medical robot leasing projects, demonstrating to the world the latest achievements of China's self-reliance and strength in high-end medical equipment.
· China Medical News Information Association Leads Mainstream Media Group into Weimai Medical
On September 19, the China Medical News Information Association led a group of mainstream media to visit Weimai Medical, embarking on an exciting journey to explore the forefront of medical technology. Yang He, CEO of Weimai Medical, warmly received President Shen Jingwang and his delegation. Centering around an interventional surgical robot as the "main character," they narrated a moving story of China's high-end medical technology achieving self-reliance and strength.
· Two Products Receive CE Certification!
· Two Products Receive CE Certification!
On September 23, multiple models of Taikon・Space Series DSA and Phoenix・Flamingo Series Mobile C-Arms independently developed by Weimai Medical successfully obtained CE certification in accordance with the MDR 2017/745 regulation. This is not only an important sign that the quality and technical level of Weimai Medical's products have gained international recognition, but also lays a solid foundation for its further expansion into the global interventional medical equipment market.
· Economic Development Zone Organizes Hong Kong Exchange for Regional Innovative Enterprises to Promote International Development of Yizhuang Biomedical Industry
Recently, the BIOHK2025 Hong Kong International Biotechnology Forum & Exhibition, hosted by the Hong Kong Biotechnology Association, concluded successfully at the Hong Kong Convention and Exhibition Center. Under the coordination and organization of the Economic Development Zone, Weimai Medical joined hands with several innovative enterprises in the zone to form the "Yizhuang Biomedical Delegation." Invited as a group, they made an appearance at the exhibition, focusing on the objectives of "attracting projects, promoting transformation, and expanding markets," and carried out a series of high-standard business exchange activities, showcasing to the world Beijing Yizhuang's innovative strength and openness as a highland of China's pharmaceuticals and health industry.
· Interventional Robot Invited as Model Enterprise to Collaborate with Top Cardiac Institutions in Designing the Future Cath Lab Blueprint
Recently, the China Heart Congress 2025 (CHC2025) was grandly held at the Beijing National Convention Center. As one of the most influential academic events in the global cardiovascular field, this year's conference brought together top experts and cutting-edge technologies from both within and outside China.Weimai Medical, as an invited model enterprise in the interventional robotics track, deeply participated in the seminar on future innovative catheterization lab models. The company's CTO, Jie Jing, delivered a keynote speech titled "Technological Progress of Cardiovascular Interventional Surgical Robots and Their Application in Future Catheterization Labs," systematically showcasing the underlying technical logic and clinical application prospects of the "eye-hand-brain" integrated interventional robot.Sparked high attention from the attending experts.
Aomo Pharmaceuticals
· Assist Partners in Successful API Registration
Recently, Aomo Pharmaceuticals assisted its partners, Jilin Xidian Pharmaceutical and Shandong Luxi Pharmaceutical, in successfully filing for API registration.
Aomo Pharmaceuticals
· Assist Partners in Successful API Registration
Recently, Aomo Pharmaceuticals assisted its partners, Jilin Xidian Pharmaceutical and Shandong Luxi Pharmaceutical, in successfully filing for API registration.
Atom Therapeutics
· ABP-671, an innovative anti-gout drug, achieves positive results in global Phase IIb/III clinical trials
Atom Therapeutics
· ABP-671, an innovative anti-gout drug, achieves positive results in global Phase IIb/III clinical trials
On September 8, Atom Therapeutics announced highly positive results from the global Phase IIb/III clinical trial of ABP-671 for the treatment of gout. This trial is a multicenter, randomized, double-blind, allopurinol-positive (Treat-to-Target), and placebo-controlled global study conducted across multiple countries and regions, including the United States, Europe, Australia, Latin America, and Taiwan, with a primary endpoint assessment period of six months.
· CUA2025 Successfully Convened
On September 4, the 32nd Chinese Urological Association Annual Meeting (CUA2025) grandly opened at the Dalian International Conference Center. Jiangsu New Element Medical Technology Co., Ltd. showcased its innovative extracorporeal shock wave lithotripsy products and solutions, engaging in in-depth exchanges with attending experts and scholars.
Hannuo Medical
· Hannuo Medical Appears at CCCC 2025
Hannuo Medical
· Hannuo Medical Appears at CCCC 2025
From September 4th to 7th, the 16th Annual Meeting of the Intensive Care Medicine Physicians Branch of the Chinese Medical Doctor Association and the Chinese Critical Care Medicine Conference (CCCC 2025) was successfully held in Nanjing, Jiangsu. Hannov Medical's portable stent made its first public appearance at this conference, with its lightweight and portable design drawing significant attention from many attending experts and clinicians.
· Sino-German ECMO Technology Innovation and Industrial Development Summit Successfully Held at Hannover Medical
On September 12, the "New Era of Low-Altitude Medical Rescue: Sino-German ECMO Technology Innovation and Industry Development Summit," hosted by Hannovital Medical, was successfully held at the Hannovital Medical headquarters in Bao'an, Shenzhen. Ms. Liu Yang, Chairwoman of Hannovital Medical, shared a strategic vision titled “Systematic Layout of Lifemotion® ECMO in the Field of Three-Dimensional Rescue.”
Tianqin Biotech
· Multiple Experts Invited to Attend the 2025 13th Annual Conference of Toxicology in Pharmaceuticals
· Sino-German ECMO Technology Innovation and Industrial Development Summit Successfully Held at Hannover Medical
On September 12, the "New Era of Low-Altitude Medical Rescue: Sino-German ECMO Technology Innovation and Industry Development Summit," hosted by Hannovital Medical, was successfully held at the Hannovital Medical headquarters in Bao'an, Shenzhen. Ms. Liu Yang, Chairwoman of Hannovital Medical, shared a strategic vision titled “Systematic Layout of Lifemotion® ECMO in the Field of Three-Dimensional Rescue.”
Tianqin Biotech
· Multiple Experts Invited to Attend the 2025 13th Annual Conference of Toxicology in Pharmaceuticals
Tianqin Biotech
· Multiple Experts Invited to Attend the 2025 13th Annual Conference of Toxicology in Pharmaceuticals
From September 11 to September 13, the "13th Annual Conference of Drug Toxicology" jointly hosted by the Drug Toxicology and Safety Evaluation Committee of the Chinese Society of Toxicology, and organized by the Yangtze River Delta National Innovation Center (Zhejiang), was grandly held at Nanhu Hotel in Jiaxing, Zhejiang. Several experts from Healthgen Biotech were invited to deliver insightful presentations at the main venue and multiple thematic sub-venues, sharing their cutting-edge thoughts and expertise in the field of non-clinical drug safety evaluation.
Noliving Biotech
· Unveiling NO Full Ecosystem Solution at CCCC2025
Noliving Biotech
· Unveiling NO Full Ecosystem Solution at CCCC2025
September 5th-7th, the 16th Annual Meeting of the Chinese Medical Doctor Association's Critical Care Medicine Branch and the Chinese Critical Care Conference (CCCC2025) was grandly held in Nanjing, Jiangsu Province. Nuolin Biotech showcased its full NO ecosystem solution.
· Precision Strategies to Break the Treatment Dilemma of ARDS
On September 22, the Third Quarter Academic Conference of 2025 of the Shanghai Medical Association's Critical Emergency Rescue Branch was successfully held at the Shanghai National Convention and Exhibition Center. The special report by Director Xing Shunpeng, titled "Inhaled Nitric Oxide (iNO) Therapy for ARDS Patients," systematically elaborated on the crucial role of inhaled nitric oxide therapy in correcting hypoxemia and improving pulmonary vascular function, providing significant clinical evidence. This aligns closely with NOLV Biotech’s commitment to continuous innovation in the iNO treatment field.
Innolook
· Showcased Heavyweight Product: Intravascular Dual-Mode Imaging System at PCI Salon-2025
Innolook
· Showcased Heavyweight Product: Intravascular Dual-Mode Imaging System at PCI Salon-2025
Recently, the "2025 Sichuan Province Coronary Heart Disease Intervention Salon and Complex Coronary Artery Case Demonstration Conference (PCI Salon-2025)" successfully concluded in Chengdu, Sichuan. During the conference, Inspiral Medical showcased its heavyweight product — the dual-modal intravascular imaging system.
· Imaging Insights' "Small Probe" Successfully Implemented in Three Benchmark Hospitals in Shanxi Province
Recently, the small probe endoscopic ultrasound series independently developed by Yingmeida has been continuously implemented in three benchmark hospitals in Shanxi Province — Shanxi Provincial People's Hospital, First Hospital of Shanxi Medical University, and Second Hospital of Shanxi Medical University. With its efficient and precise diagnostic capabilities, it provides higher quality medical services for patients in Shanxi and surrounding areas.
Century Kaitai
· 2025 CCOS Series Academic Activities Successfully Concluded
Century Kaitai
· 2025 CCOS Series Academic Activities Successfully Concluded
Recently, the 29th National Ophthalmology Academic Conference of the Chinese Medical Association (CCOS 2025) was grandly held at the Hangzhou International Expo Center. Century KANGTAI, with the theme "The Light of the Century · Illuminating the Future," created a series of fascinating academic feasts, gathering top ophthalmic expertise in China. Focusing on the latest advancements in refractive cataract surgery and optometric technology, it presented an academic event full of intellectual exchange and technological showcase for ophthalmologists across China.
· Professor Zhang Guangbin Shares Outstanding Data on the Launch of the Lightricity® Trifocal Plus Crystal
Recently, at the CCOS2025 conference, Professor Zhang Guangbin presented for the first time the clinical data of the Lightrict® Trifocal Plus Intraocular Lens (D615L) from a multi-center post-market study in China (as of August 31, 2025, n=127 eyes). The results showed a stable upward trend in postoperative visual acuity.
Huahao Zhongtian
· The First Global Study of Utidelone Capsules Initiated
Huahao Zhongtian
· The First Global Study of Utidelone Capsules Initiated
On September 11, Huahao Zhongtian announced that the first patient dosing has been completed in the international multicenter Phase II/III clinical trial (BG02-2502) of UTD2, one of the indication pipelines for its core product, Utidelone Capsules (UTD2), for the treatment of patients with platinum-resistant advanced epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. This marks the first international multicenter clinical study globally initiated by UTD2 for the treatment of advanced solid tumors following the completion of its Phase I clinical trial in the United States.
· First Patient Dosed in Global Clinical Trial of Utidelone Capsules as First-Line Treatment for Advanced Gastric Cancer
On September 12, Huahao Zhongtian announced that the first patient dosing has been completed in the international multicenter Phase II/III clinical study (BG02-2404) of UTD2 as a first-line treatment for locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma. This is the second international multicenter clinical study initiated for UTD2 following advanced ovarian cancer.
· Breaking the Deadlock in Pancreatic Cancer! Utidelone Once Again Receives FDA Orphan Drug Designation
On September 25, Huahao Zhongtian announced that its core product, Utidelone, was once again recognized by the U.S. Food and Drug Administration (FDA).Abbreviated as "FDA") granted orphan drug designation for the indication of pancreatic cancer. This is the third orphan drug designation that Utidelone has received from the FDA, following breast cancer brain metastasis and gastric cancer.
· Key Technology of Synthetic Biology Genetically Engineered Microorganisms Granted U.S. PCT Patent Authorization
On September 19, Huahao Zhongtian announced that a key synthetic biology technology independently developed by the company had been granted a patent by the United States Patent and Trademark Office. The patent covers a high-quality and efficient genetically engineered strain, as well as a method for fermenting and producing Utidelone using this genetically engineered strain. This is a core patent in the intellectual property protection system for Utidelone, with a protection period extending until 2041. The patent was authorized through the PCT international application route, and its counterpart patents have also been granted in countries and regions such as China and Japan.
· Breaking the Deadlock in Pancreatic Cancer! Utidelone Once Again Receives FDA Orphan Drug Designation
On September 25, Huahao Zhongtian announced that its core product, Utidelone, was once again recognized by the U.S. Food and Drug Administration (FDA).Abbreviated as "FDA") granted orphan drug designation for the indication of pancreatic cancer. This is the third orphan drug designation that Utidelone has received from the FDA, following breast cancer brain metastasis and gastric cancer.
· Key Technology of Synthetic Biology Genetically Engineered Microorganisms Granted U.S. PCT Patent Authorization
On September 19, Huahao Zhongtian announced that a key synthetic biology technology independently developed by the company had been granted a patent by the United States Patent and Trademark Office. The patent covers a high-quality and efficient genetically engineered strain, as well as a method for fermenting and producing Utidelone using this genetically engineered strain. This is a core patent in the intellectual property protection system for Utidelone, with a protection period extending until 2041. The patent was authorized through the PCT international application route, and its counterpart patents have also been granted in countries and regions such as China and Japan.
· Key Technology of Synthetic Biology Genetically Engineered Microorganisms Granted U.S. PCT Patent Authorization
On September 19, Huahao Zhongtian announced that a key synthetic biology technology independently developed by the company had been granted a patent by the United States Patent and Trademark Office. The patent covers a high-quality and efficient genetically engineered strain, as well as a method for fermenting and producing Utidelone using this genetically engineered strain. This is a core patent in the intellectual property protection system for Utidelone, with a protection period extending until 2041. The patent was authorized through the PCT international application route, and its counterpart patents have also been granted in countries and regions such as China and Japan.
Harbour BioMed
· Dr. Wang Jinsong's Speech at Legend Capital Forum
Harbour BioMed
· Dr. Wang Jinsong's Speech at Legend Capital Forum
On September 10, the Junlian Capital 2025 CFO & CHO Joint Forum, themed "Goal-Driven, Breaking Through for Growth," was held in Beijing. The event brought together more than 170 CEOs, CFOs, CHOs, and senior executive representatives from over 80 companies. Dr. Wang Jinsong, Founder, Chairman, and CEO of Harbour BioMed, was invited to attend and served as the first keynote speaker. He delivered a speech titled "Harbour BioMed, A Decade of Innovation: Driving Countercyclical Growth through Technological Breakthroughs and Innovative Business Models," sharing insights into the development history and future trends of China's innovative pharmaceutical industry.
Reindeer Biotech
· Research Results of Idecabtagene Vicleucel Injection for the Treatment of Multiple Sclerosis Presented at 2025 ANA and ECTRIMS
Reindeer Biotech
· Research Results of Idecabtagene Vicleucel Injection for the Treatment of Multiple Sclerosis Presented at 2025 ANA and ECTRIMS
On September 12, IASO Biotherapeutics announced that the research results of its self-developed fully human BCMA-targeted CAR-T cell therapy, Eque-cel (Inebilizumab) Injection, for the treatment of Progressive Multiple Sclerosis (PMS), will be successively presented at the 2025 American Neurological Association (ANA) Annual Meeting and the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Conference, in the form of a poster presentation and oral report, respectively.
· Global Strategic Cooperation Reached with SMAVEW to Jointly Expand the Overseas Market for Integrated Cell Therapy Solutions Made in China
On September 9, Icarus Bio and CyGenuity officially signed a global strategic cooperation agreement to jointly promote the integrated overseas expansion of China-produced advanced cell therapy drug industry chains. Dr. Shang Yuanfang, founder, chairman, and CEO of CyGenuity, and Zhang Jinhua, founder, chairman, and CEO of Icarus Bio, attended the signing ceremony together.
· Heavyweight Release: CAR-T Product Focusa® 3-Year Follow-Up Data in Treating Multiple Myeloma Achieves Multiple Breakthroughs
On September 19, IASO Biotherapeutics announced the official release of the 36-month long-term follow-up data from the FUMANBA-1 study on its self-developed fully human BCMA-targeted CAR-T cell therapy product, Focusa® (Eque-cel, Idecabtagene Vicleucel), for the treatment of relapsed/refractory multiple myeloma (R/R MM) during the annual meeting of the International Myeloma Society (IMS). The study results further confirmed that Focusa® can bring deep and durable efficacy to R/R MM patients (including those with high-risk features) while maintaining controllable long-term safety, significantly improving patients' long-term quality of life.
· Five CAR-T Products Pass Expert Review for Commercial Insurance Innovative Drug List, Icarus Bio's Product Included
On September 20, the National Healthcare Security Administration announced that the expert review for the 2025 adjustment of the National Basic Medical Insurance Drug List and the Commercial Health Insurance Innovative Drug List has concluded. Notably, all five domestically produced CAR-T therapies have passed the expert review for inclusion in the Commercial Health Insurance Innovative Drug List. Among them,Caribou Biosciences' product Ixazomib Injection is listed.。
Jingze Biotech
· Strategic cooperation reached with Kangzhe Pharmaceuticals, signing commercial agreements around multiple core products.
Jingze Biotech
· Strategic cooperation reached with Kangzhe Pharmaceuticals, signing commercial agreements around multiple core products.
Recently, Jingze Biotech and an affiliate of Chemshark Pharmaceuticals reached a strategic cooperation. They signed commercial agreements for several core products, jointly expanding the markets in and outside China, injecting strong momentum into the commercialization process of the company's products, and accelerating the goal of becoming a leading enterprise in the fields of assisted reproduction and ophthalmology.
Bionovo
· First-in-class RSK bifunctional degrader GT818 pipeline Pre-IND submission to CDE for proposed research on advanced malignant tumors
Bionovo
· First-in-class RSK bifunctional degrader GT818 pipeline Pre-IND submission to CDE for proposed research on advanced malignant tumors
Bionovo
· First-in-class RSK bifunctional degrader GT818 pipeline Pre-IND submission to CDE for proposed research on advanced malignant tumors
Bionovo
· First-in-class RSK bifunctional degrader GT818 pipeline Pre-IND submission to CDE for proposed research on advanced malignant tumors
On September 18, Gluetacs Therapeutics announced the successful submission of a Pre-IND application to the National Medical Products Administration (CDE) for the bifunctional degrader pipeline GT818, developed based on the GlueTacs® platform. This marks the official launch of the China-U.S. dual registration clinical development process for this innovative drug, with the company planning to complete the enrollment of the first patient by early 2026.
Tiangang Medino
· Two Innovative Drugs Initiate Phase I Clinical Trials in China
Tiangang Medino
· Two Innovative Drugs Initiate Phase I Clinical Trials in China
Tiangang Medino
· Two Innovative Drugs Initiate Phase I Clinical Trials in China
Tiangang Medino
· Two Innovative Drugs Initiate Phase I Clinical Trials in China
Recently, Hefei Tian Gang Immunological Drugs Co., Ltd. has initiated a Phase I clinical trial of its monoclonal antibody drug at the Fudan University-affiliated Cancer Hospital and completed the enrollment and dosing of the first patient. Thus far, Tian Gang Medical Innovation has brought two innovative immunotherapy drugs—both unique in China and ranking second globally—to the clinical trial stage, potentially offering new treatment options for cancer patients.
· Invited to Attend the 3rd Hefei Biomedical Innovation and Industry Conference, Leading the Showcase of Cutting-edge Breakthroughs in Immunotherapy
September 4th-6th, the 3rd Hefei Biomedical Innovation and Industry Conference was grandly held in Hefei. Professor Zhigang Tian, founder of Hefei Tian Gang Immunopharmaceutical Co., Ltd., Dr. Guoshuai Cao, Vice President of R&D, and Dr. Xiaohu Zheng, Vice President of Operations, were invited to attend and give presentations.
· Provincial Party Secretary Liang Yanshun Inspects Tian Gang Medical Innovation Product Achievements on Site
On the morning of September 1, Provincial Party Secretary Liang Yanshun conducted a survey at the Greater Health Research Institute of Hefei Comprehensive National Science Center and presided over a symposium. He emphasized the need to thoroughly study and implement the important statements of General Secretary Xi Jinping on the construction of Healthy China and his important speech during his inspection of Anhui. He called for leveraging the bridging role of high-level scientific innovation platforms to promote the deep integration of scientific and industrial innovation, accelerate progress in the new field of Greater Health, and make due contributions to the construction of Healthy China.
Kaituo Biotech
· Join Hands with TOFUZ to Explore the Frontier of RNA-LNP Drug CMC Processes
Kaituo Biotech
· Join Hands with TOFUZ to Explore the Frontier of RNA-LNP Drug CMC Processes
Kaituo Biotech
· Join Hands with TOFUZ to Explore the Frontier of RNA-LNP Drug CMC Processes
On September 25, Dr. Ri Huang, Head of LNP Formulation Process Development at Cadon Biotech, was invited to share the full-process CMC development and targeted delivery solutions for mRNA-LNP drugs.
· Collaborate with Tianze Cloud-Tech LNP Technology Platform to Accelerate Patent Achievement Transformation
Recently,SMAVEW Collaborates withViLNP® Lipid Nanoparticle Delivery Technology Platform of Tianzeyun has achieved 4 external technology licenses, covering multiple fields such as mRNA tumor vaccines, metabolic diseases, in-vivo CAR-T, and gene editing. Relevant pipelines have entered the IND or IIT stage.
Wide Hill Orthopedics
· Global Event Gains Continuous Attention, Total Hip and Knee Replacement Solutions Lead Innovation Trend
Recently, BROADHIP Orthopedics has made frequent appearances on the international medical stage, successively participating in three major industry events: the ICJR exhibition in Egypt, the SICOT World Orthopedic Congress, and the Peru Medical Exhibition. The company showcased its cutting-edge products and systematic solutions in total hip and total knee replacement, gaining widespread attention and recognition from the global orthopedic community.
Lingyi Biotech
· Gaucher Disease AAV Gene Therapy LY-M001 Initiates Phase II Clinical Trial
Wide Hill Orthopedics
· Global Event Gains Continuous Attention, Total Hip and Knee Replacement Solutions Lead Innovation Trend
Recently, BROADHIP Orthopedics has made frequent appearances on the international medical stage, successively participating in three major industry events: the ICJR exhibition in Egypt, the SICOT World Orthopedic Congress, and the Peru Medical Exhibition. The company showcased its cutting-edge products and systematic solutions in total hip and total knee replacement, gaining widespread attention and recognition from the global orthopedic community.
Lingyi Biotech
· Gaucher Disease AAV Gene Therapy LY-M001 Initiates Phase II Clinical Trial
Wide Hill Orthopedics
· Global Event Gains Continuous Attention, Total Hip and Knee Replacement Solutions Lead Innovation Trend
Recently, BROADHIP Orthopedics has made frequent appearances on the international medical stage, successively participating in three major industry events: the ICJR exhibition in Egypt, the SICOT World Orthopedic Congress, and the Peru Medical Exhibition. The company showcased its cutting-edge products and systematic solutions in total hip and total knee replacement, gaining widespread attention and recognition from the global orthopedic community.
Lingyi Biotech
· Gaucher Disease AAV Gene Therapy LY-M001 Initiates Phase II Clinical Trial
Lingyi Biotech
· Gaucher Disease AAV Gene Therapy LY-M001 Initiates Phase II Clinical Trial
Lingyi Biotech
· Gaucher Disease AAV Gene Therapy LY-M001 Initiates Phase II Clinical Trial
Recently, Lingyi (Hangzhou) Biotechnology Co., Ltd. announced that the Phase II clinical trial of its self-developed LY-M001 injection for the treatment of Type I Gaucher's disease has officially started, rapidly advancing multi-center clinical research. This is also the first AAV gene therapy drug for Gaucher's disease in China to enter the Phase II clinical stage.
Huanma Biotech
· A Delegation from the Macao Special Administrative Region's Investment and Promotion Agency Visits Huanma Bio for Exchange
On September 19, Xie Yongqiang, Chairman of the Investment Promotion and Administrative Committee of Macao Special Administrative Region, and Chen Zurong, Deputy Director of the Economic and Technological Development Bureau, visited Huanma Biomedical Co., Ltd. in Shanghai for an exchange. They were accompanied by Yang Yun, Chairman and Chief Technology Officer of Huanma Bio, CEO Tang Chenxiang, and other relevant executives.
Huanma Biotech
· A Delegation from the Macao Special Administrative Region's Investment and Promotion Agency Visits Huanma Bio for Exchange
On September 19, Xie Yongqiang, Chairman of the Investment Promotion and Administrative Committee of Macao Special Administrative Region, and Chen Zurong, Deputy Director of the Economic and Technological Development Bureau, visited Huanma Biomedical Co., Ltd. in Shanghai for an exchange. They were accompanied by Yang Yun, Chairman and Chief Technology Officer of Huanma Bio, CEO Tang Chenxiang, and other relevant executives.
Huanma Biotech
· A Delegation from the Macao Special Administrative Region's Investment and Promotion Agency Visits Huanma Bio for Exchange
On September 19, Xie Yongqiang, Chairman of the Investment Promotion and Administrative Committee of Macao Special Administrative Region, and Chen Zurong, Deputy Director of the Economic and Technological Development Bureau, visited Huanma Biomedical Co., Ltd. in Shanghai for an exchange. They were accompanied by Yang Yun, Chairman and Chief Technology Officer of Huanma Bio, CEO Tang Chenxiang, and other relevant executives.
· Strategic Cooperation Reached with DerivTech to Jointly Explore the New Future of AI-Driven Drug Development
Recently, Healthgen Biotech and SMAVEW jointly announced that they have officially reached a three-year strategic cooperation agreement. Based on a digital platform, the two parties will jointly explore the deep application of AI agents in the field of novel RNA drug research and development, aiming to accelerate the R&D process of innovative therapies and create a new paradigm for intelligent research and development.
Zifu Medical
· Empowering Health Management with Digital Intelligence, Driving Discipline Development through Innovation
From September 19th to 21st, the 18th Health Service Industry Conference and the 16th Academic Conference on Health Management of the Chinese Medical Association was successfully held in Chengdu, the "Land of Abundance." ZiFu Medical, with its globally leading magnetically controlled capsule endoscopy technology, emerged as the most prominent "Digital Intelligence Leader."
Zifu Medical
· Empowering Health Management with Digital Intelligence, Driving Discipline Development through Innovation
From September 19th to 21st, the 18th Health Service Industry Conference and the 16th Academic Conference on Health Management of the Chinese Medical Association was successfully held in Chengdu, the "Land of Abundance." ZiFu Medical, with its globally leading magnetically controlled capsule endoscopy technology, emerged as the most prominent "Digital Intelligence Leader."
Zifu Medical
· Empowering Health Management with Digital Intelligence, Driving Discipline Development through Innovation
From September 19th to 21st, the 18th Health Service Industry Conference and the 16th Academic Conference on Health Management of the Chinese Medical Association was successfully held in Chengdu, the "Land of Abundance." ZiFu Medical, with its globally leading magnetically controlled capsule endoscopy technology, emerged as the most prominent "Digital Intelligence Leader."
Baymei Pharmaceuticals
· New Product TWYNEO® (Tretinoin and Benzoyl Peroxide Cream) in Dermatology Receives Approval for Clinical Drug Trials
Baymei Pharmaceuticals
· New Product TWYNEO® (Tretinoin and Benzoyl Peroxide Cream) in Dermatology Receives Approval for Clinical Drug Trials
On September 25, Beimei Pharmaceuticals' TWYNEO® (Tretinoin and Benzoyl Peroxide Cream) received clinical trial approval from the National Medical Products Administration, granting consent to "conduct a multi-center, randomized, double-blind, placebo-controlled parallel group Phase III clinical study on the efficacy and safety in patients aged 9 years and older with acne vulgaris."
Anke Biotech
· Governor Wang Qingxian Inspects the World Manufacturing Conference, Stops at Anke Biotech Exhibition Area to Learn about the Company's R&D and Innovation Achievements
Anke Biotech
· Governor Wang Qingxian Inspects the World Manufacturing Conference, Stops at Anke Biotech Exhibition Area to Learn about the Company's R&D and Innovation Achievements
On September 20, the 2025 World Manufacturing Conference grandly opened at the Hefei Binhu International Convention and Exhibition Center. As a leading enterprise in Anhui Province's biopharmaceutical industry, Anke Bio was invited to participate for the fourth consecutive time. The company showcased its innovative products and solutions in the fields of children's growth and development, anti-tumor, assisted reproduction, and autoimmune diseases, such as Ansomone® Somatropin Injection, Antistine® Trastuzumab Injection, Shineova® Follitropin Alfa N01, and PA3-17 Injection. This highlighted the company's systematic layout and cutting-edge capabilities in the "intelligent manufacturing" of biopharmaceuticals.
US-China Dual Harmony
· "Precision PCI" Series Debuts at the China International Fair for Trade in Services
US-China Dual Harmony
· "Precision PCI" Series Debuts at the China International Fair for Trade in Services
Recently, at the 2025 China International Fair for Trade in Services (CIFTIS), a national, international, and comprehensive service trade platform, Beijing Meizhong Shuanghe Medical Device Co., Ltd. made a significant appearance with its "Precision PCI" series of innovative products, fully showcasing China's technological breakthroughs in high-end medical equipment and innovative achievements in the field of trade in services.
Andaoway Pharmaceuticals
· First-in-Class Pan-Anemia Therapy Launches First Phase III Clinical Trial
Andaoway Pharmaceuticals
· First-in-Class Pan-Anemia Therapy Launches First Phase III Clinical Trial
On September 11, the official website of the Drug Clinical Trial Registration and Information Disclosure Platform showed that Andao Pharmaceuticals registered a Phase III clinical trial for the oral AND017 capsule in treating anemia in subjects with dialysis-dependent chronic kidney disease (DD-CKD). Public information indicates that this is the first Phase III trial initiated for this drug.
InnoMed Pharmaceuticals
· The Phase Ib/IIa Clinical Trial Data of YN001 Released Globally for the First Time
InnoMed Pharmaceuticals
· The Phase Ib/IIa Clinical Trial Data of YN001 Released Globally for the First Time
On September 1, at the ESC Congress 2025, the annual meeting of the European Society of Cardiology held in Madrid, Spain, the Phase Ib/IIa clinical trial data for YN001, the first innovative drug by Innopharm to reverse atherosclerotic plaques, was released globally for the first time.
SMAVEW
· China's Only nCLE, Cellular-Level Imaging Facilitates New Breakthroughs in Respiratory Disease Diagnosis and Treatment
From September 11 to 14, the Chinese Medical Association Annual Conference on Respiratory Diseases - 2025 was grandly held at the Changsha International Convention Center. On this academic stage, Jingwei Shida showcased China's only probe-based respiratory confocal laser endomicroscopy (nCLE) and demonstrated the application potential of cellular-level imaging in the diagnosis and treatment of respiratory diseases through booth displays, special lectures, and academic exchanges.
SMAVEW
· China's Only nCLE, Cellular-Level Imaging Facilitates New Breakthroughs in Respiratory Disease Diagnosis and Treatment
From September 11 to 14, the Chinese Medical Association Annual Conference on Respiratory Diseases - 2025 was grandly held at the Changsha International Convention Center. On this academic stage, Jingwei Shida showcased China's only probe-based respiratory confocal laser endomicroscopy (nCLE) and demonstrated the application potential of cellular-level imaging in the diagnosis and treatment of respiratory diseases through booth displays, special lectures, and academic exchanges.
· Multiple Regions BIOPSEE® Beixi® Confocal Academic Conference Discusses New Advances in Precision Diagnosis and Treatment of Digestive and Respiratory Systems
From September 26 to 28, the Datong City Digestive Internal Medicine Quality Control Center Work Conference, the 2025 Guangzhou Digestive Forum, and the Annual Meeting of the Nanning Medical Association Respiratory Disease Branch will be held concurrently, focusing on the latest advances in diagnosis, treatment, and technical standards in the fields of digestion and respiration. As a pioneer in the field of microscopic medicine, Jingwei Shida will showcase the BIOPSEE® Beixi® Confocal Microendoscopy product, the sole demonstration product of the Ministry of Science and Technology's confocal clinical application demonstration project, at the conference. Experts and peers are welcome to visit the booth, engage in in-depth discussions about the clinical application experiences of cutting-edge technologies, and jointly explore new frontiers in the precise diagnosis and treatment of digestive diseases.
· Multiple Regions BIOPSEE® Beixi® Confocal Academic Conference Discusses New Advances in Precision Diagnosis and Treatment of Digestive and Respiratory Systems
From September 26 to 28, the Datong City Digestive Internal Medicine Quality Control Center Work Conference, the 2025 Guangzhou Digestive Forum, and the Annual Meeting of the Nanning Medical Association Respiratory Disease Branch will be held concurrently, focusing on the latest advances in diagnosis, treatment, and technical standards in the fields of digestion and respiration. As a pioneer in the field of microscopic medicine, Jingwei Shida will showcase the BIOPSEE® Beixi® Confocal Microendoscopy product, the sole demonstration product of the Ministry of Science and Technology's confocal clinical application demonstration project, at the conference. Experts and peers are welcome to visit the booth, engage in in-depth discussions about the clinical application experiences of cutting-edge technologies, and jointly explore new frontiers in the precise diagnosis and treatment of digestive diseases.
HaploX
· Powerful Alliance! HaploX and FanYin Medicine Reach Strategic Cooperation, Jointly Initiating a New Chapter in Precision Medicine
September 22, a professional immunomics testing service company in China, Fan Yin Medical, and a leading company in China,Precision MedicineOfficially reached a strategic cooperation with HaploX, a national high-tech enterprise in gene big data and a specialized and sophisticated "Little Giant" enterprise.
· 11th Anniversary and 1st Anniversary of Hong Kong Medical Laboratory
Recently, HaploX Group announced the 1st anniversary of its Hong Kong Medical Laboratory.
· HaploX Labs in Hong Kong, Shenzhen, and Shangrao Obtain Prestigious CAP-NGSST-A Certification
Recently, the College of American Pathologists (CAP) released the 2025 CAP-NGSST-A Proficiency Testing Assessment Report. Shenzhen HaploX Medical Laboratory, Shangrao HaploX Laboratory, and HAPLOX GENETECH (HONG KONG) LIMITED all achieved perfect scores in this assessment. This marks another comprehensive recognition by CAP of HaploX's technical management standards, indicating that HaploX’s diagnostic quality and standards remain at the forefront of international excellence and have gained recognition from authoritative global institutions.
· Standardizing Precision Oncology, Innovation Leads the New Journey in Cancer Treatment
From September 10th to 14th, the 28th CSCO Annual Meeting, jointly organized by the Chinese Society of Clinical Oncology (CSCO) and the Beijing Xisike Clinical Oncology Research Foundation, was grandly held in the beautiful Spring City of Jinan. HaploX, as a co-organizer of the "Application of Multi-Omics New Technologies in Cancer Research and Practice" session hosted by the CSCO Tumor Biomarker Expert Committee, participated in this year’s academic meeting. In this session, Professor Mingxin Pan from Zhujiang Hospital of Southern Medical University shared the presentation titled "Exploration of MRD Application in Post-Radical Hepatocellular Carcinoma Surgery – Interim Data," which showcased promising data on MRD within the field of liver cancer.
· Full Marks Achieved in the 2025 NCCL Inter-laboratory Quality Assessment for High-throughput Sequencing Detection of Tumor Cell-free DNA Gene Mutations
Recently, the National Center for Clinical Laboratories (NCCL) of the National Health Commission of China released the 2025 External Quality Assessment Report on High-Throughput Sequencing Detection of Tumor Cell-Free DNA Gene Mutations. Shenzhen HaploX Medical Laboratory achieved a perfect score in this evaluation, marking another comprehensive recognition by NCCL of HaploX's technical management standards. This achievement indicates that HaploX consistently maintains its diagnostic quality and standards at the highest level and has earned recognition from authoritative organizations.
HaploX
· Powerful Alliance! HaploX and FanYin Medicine Reach Strategic Cooperation, Jointly Initiating a New Chapter in Precision Medicine
September 22, a professional immunomics testing service company in China, Fan Yin Medical, and a leading company in China,Precision MedicineOfficially reached a strategic cooperation with HaploX, a national high-tech enterprise in gene big data and a specialized and sophisticated "Little Giant" enterprise.
· 11th Anniversary and 1st Anniversary of Hong Kong Medical Laboratory
Recently, HaploX Group announced the 1st anniversary of its Hong Kong Medical Laboratory.
· HaploX Labs in Hong Kong, Shenzhen, and Shangrao Obtain Prestigious CAP-NGSST-A Certification
Recently, the College of American Pathologists (CAP) released the 2025 CAP-NGSST-A Proficiency Testing Assessment Report. Shenzhen HaploX Medical Laboratory, Shangrao HaploX Laboratory, and HAPLOX GENETECH (HONG KONG) LIMITED all achieved perfect scores in this assessment. This marks another comprehensive recognition by CAP of HaploX's technical management standards, indicating that HaploX’s diagnostic quality and standards remain at the forefront of international excellence and have gained recognition from authoritative global institutions.
· Standardizing Precision Oncology, Innovation Leads the New Journey in Cancer Treatment
From September 10th to 14th, the 28th CSCO Annual Meeting, jointly organized by the Chinese Society of Clinical Oncology (CSCO) and the Beijing Xisike Clinical Oncology Research Foundation, was grandly held in the beautiful Spring City of Jinan. HaploX, as a co-organizer of the "Application of Multi-Omics New Technologies in Cancer Research and Practice" session hosted by the CSCO Tumor Biomarker Expert Committee, participated in this year’s academic meeting. In this session, Professor Mingxin Pan from Zhujiang Hospital of Southern Medical University shared the presentation titled "Exploration of MRD Application in Post-Radical Hepatocellular Carcinoma Surgery – Interim Data," which showcased promising data on MRD within the field of liver cancer.
· Full Marks Achieved in the 2025 NCCL Inter-laboratory Quality Assessment for High-throughput Sequencing Detection of Tumor Cell-free DNA Gene Mutations
Recently, the National Center for Clinical Laboratories (NCCL) of the National Health Commission of China released the 2025 External Quality Assessment Report on High-Throughput Sequencing Detection of Tumor Cell-Free DNA Gene Mutations. Shenzhen HaploX Medical Laboratory achieved a perfect score in this evaluation, marking another comprehensive recognition by NCCL of HaploX's technical management standards. This achievement indicates that HaploX consistently maintains its diagnostic quality and standards at the highest level and has earned recognition from authoritative organizations.
· 11th Anniversary and 1st Anniversary of Hong Kong Medical Laboratory
Recently, HaploX Group announced the 1st anniversary of its Hong Kong Medical Laboratory.
· HaploX Labs in Hong Kong, Shenzhen, and Shangrao Obtain Prestigious CAP-NGSST-A Certification
Recently, the College of American Pathologists (CAP) released the 2025 CAP-NGSST-A Proficiency Testing Assessment Report. Shenzhen HaploX Medical Laboratory, Shangrao HaploX Laboratory, and HAPLOX GENETECH (HONG KONG) LIMITED all achieved perfect scores in this assessment. This marks another comprehensive recognition by CAP of HaploX's technical management standards, indicating that HaploX’s diagnostic quality and standards remain at the forefront of international excellence and have gained recognition from authoritative global institutions.
· Standardizing Precision Oncology, Innovation Leads the New Journey in Cancer Treatment
From September 10th to 14th, the 28th CSCO Annual Meeting, jointly organized by the Chinese Society of Clinical Oncology (CSCO) and the Beijing Xisike Clinical Oncology Research Foundation, was grandly held in the beautiful Spring City of Jinan. HaploX, as a co-organizer of the "Application of Multi-Omics New Technologies in Cancer Research and Practice" session hosted by the CSCO Tumor Biomarker Expert Committee, participated in this year’s academic meeting. In this session, Professor Mingxin Pan from Zhujiang Hospital of Southern Medical University shared the presentation titled "Exploration of MRD Application in Post-Radical Hepatocellular Carcinoma Surgery – Interim Data," which showcased promising data on MRD within the field of liver cancer.
· Full Marks Achieved in the 2025 NCCL Inter-laboratory Quality Assessment for High-throughput Sequencing Detection of Tumor Cell-free DNA Gene Mutations
Recently, the National Center for Clinical Laboratories (NCCL) of the National Health Commission of China released the 2025 External Quality Assessment Report on High-Throughput Sequencing Detection of Tumor Cell-Free DNA Gene Mutations. Shenzhen HaploX Medical Laboratory achieved a perfect score in this evaluation, marking another comprehensive recognition by NCCL of HaploX's technical management standards. This achievement indicates that HaploX consistently maintains its diagnostic quality and standards at the highest level and has earned recognition from authoritative organizations.
Frontier Biologics
· World's First! SMAVEW's Dual-Target siRNA Drug FB7011 Offers New Treatment Option for IgA Nephropathy
Frontier Biologics
· World's First! SMAVEW's Dual-Target siRNA Drug FB7011 Offers New Treatment Option for IgA Nephropathy
From September 17 to 20, the 18th International IgA Nephropathy Symposium (IIgANN 2025) was held in Prague, Czech Republic. SMAVEW presented for the first time in an oral report the preclinical data of its self-developed dual-target small nucleic acid drug FB7011, which has the potential to be a global first-in-class innovation. This drug can simultaneously target MASP-2, a key protein in the lectin pathway of the complement system, and CFB, a key protein in the alternative pathway. By precisely intervening in the abnormal activation of the complement system, it blocks the pathogenesis of IgA nephropathy.
· Two-pronged approach! Chinese scholars present a new solution for functional cure of hepatitis B
From September 8 to 12, the 2025 International HBV Meeting was grandly held in Berlin, Germany. The latest research achievements in the direction of novel interferons from the Fudan University - Frontier Biologics Viral Infection Functional Cure University-Enterprise Joint Laboratory were presented at the conference.
Pulnovo Medical
· Heavyweight Launch of New Product Series
Pulnovo Medical
· Heavyweight Launch of New Product Series
Recently, Prima Technology has unveiled its new series of fully automatic electrochemiluminescence immunoassay analyzers, the eCL9600, eCL9900, and eCL9900i. With technological breakthroughs, they are redefining testing standards—delivering more accurate results, more efficient processes, and faster response times to empower medical institutions and safeguard life and health.
· Promed Technology's East China Industrialization Base Settles in Puhe Industrial Cooperation Demonstration Zone, Hexian County, Anhui Province
On September 21, the groundbreaking ceremony for "Futian Technology and County In Vitro Diagnostic Reagent Industrialization Project" was held inHexian, Ma'anshan CityPuhe Industrial Cooperation Demonstration ZoneGrandly Held.Liu Xiancheng, Chairman of Pulmonary Technology, President Hu Minglong, and other company leaders, as well as representatives of cooperating suppliers and dealer partners, jointly attended the groundbreaking ceremony.
· Promed Technology Shines at CTS 2025
From September 11 to 14, the Chinese Medical Association Respiratory Disease Annual Conference - 2025 (The 26th Academic Conference on Respiratory Diseases) successfully concluded at the Changsha International Convention Center. Pulmomed Technology showcased its integrated solution for respiratory interventions, injecting new momentum into industry exchange and development.
MicroCore Biotech
· Chidamide's Major Study DEB Primary Endpoint Data Released, Significantly Enhancing First-Line Double-Expressing DLBCL Treatment Efficacy
From September 10 to 14, the 28th annual academic conference of the Chinese Society of Clinical Oncology (CSCO), a grand academic feast in China's oncology field, was held in Jinan. The final results of the primary endpoint of the "head-to-head" pivotal Phase III clinical trial (DEB study) for Chidamide (brand name: Epsa®), a globally first-in-class optimal drug independently developed by Chipscreen Biosciences, used in combination with R-CHOP and as monotherapy maintenance treatment for double-expressor diffuse large B-cell lymphoma (DE-DLBCL), were announced at the lymphoma session of the conference.
· Promed Technology's East China Industrialization Base Settles in Puhe Industrial Cooperation Demonstration Zone, Hexian County, Anhui Province
On September 21, the groundbreaking ceremony for "Futian Technology and County In Vitro Diagnostic Reagent Industrialization Project" was held inHexian, Ma'anshan CityPuhe Industrial Cooperation Demonstration ZoneGrandly Held.Liu Xiancheng, Chairman of Pulmonary Technology, President Hu Minglong, and other company leaders, as well as representatives of cooperating suppliers and dealer partners, jointly attended the groundbreaking ceremony.
· Promed Technology Shines at CTS 2025
From September 11 to 14, the Chinese Medical Association Respiratory Disease Annual Conference - 2025 (The 26th Academic Conference on Respiratory Diseases) successfully concluded at the Changsha International Convention Center. Pulmomed Technology showcased its integrated solution for respiratory interventions, injecting new momentum into industry exchange and development.
· Promed Technology Shines at CTS 2025
From September 11 to 14, the Chinese Medical Association Respiratory Disease Annual Conference - 2025 (The 26th Academic Conference on Respiratory Diseases) successfully concluded at the Changsha International Convention Center. Pulmomed Technology showcased its integrated solution for respiratory interventions, injecting new momentum into industry exchange and development.
MicroCore Biotech
· Chidamide's Major Study DEB Primary Endpoint Data Released, Significantly Enhancing First-Line Double-Expressing DLBCL Treatment Efficacy
MicroCore Biotech
· Chidamide's Major Study DEB Primary Endpoint Data Released, Significantly Enhancing First-Line Double-Expressing DLBCL Treatment Efficacy
From September 10 to 14, the 28th annual academic conference of the Chinese Society of Clinical Oncology (CSCO), a grand academic feast in China's oncology field, was held in Jinan. The final results of the primary endpoint of the "head-to-head" pivotal Phase III clinical trial (DEB study) for Chidamide (brand name: Epsa®), a globally first-in-class optimal drug independently developed by Chipscreen Biosciences, used in combination with R-CHOP and as monotherapy maintenance treatment for double-expressor diffuse large B-cell lymphoma (DE-DLBCL), were announced at the lymphoma session of the conference.
Asieris Pharmaceuticals
· Dr. Pan Ke was invited to attend"Fertility Preservation for Cancer Patients in the Construction of a Childbearing-Friendly Society"
Recently, under the guidance of the China Population Association and hosted by the China Medical and Health Development Foundation, with the协办of the Beijing Health City Construction Promotion Association, a research report was organized with experts in demography, oncology, epidemiology, and reproductive science on the topic of "Protection of Fertility for Cancer Patients under the Construction of a Childbirth-Friendly Society." Dr. Pan Ke from Asieris Pharmaceuticals was invited to participate in the dialogue exchange.
· Ms. Xu Ying, Chief Business Officer, was invited to attend2025 China International Fair for Trade in Services
On September 14, the "Forum on Innovative Advances in Cancer Treatment and New Trends in Drug Development" of the 2025 China International Fair for Trade in Services was successfully held. The forum brought together experts and scholars from the field of cancer prevention and treatment in China and abroad to engage in in-depth discussions on innovative technologies in cancer treatment and new trends in drug development. Ms. Ying Xu, Chief Business Officer of Asia-Pacific Pharma, was invited to participate and share insights.
· Ounalin® Multi-City First Prescription Launched, Enhancing Accessibility of Late-Stage Breast Cancer Treatment
On September 25, Asieris Pharmaceuticals announced that its product Onarlin® (a novel microtubule inhibitor, eribulin mesylate injection, hereinafter referred to as "eribulin") for the treatment of advanced breast cancer was first prescribed in multiple cities including Yancheng, Xuzhou, Xi'an, Chengdu, and Harbin.
Asieris Pharmaceuticals
· Dr. Pan Ke was invited to attend"Fertility Preservation for Cancer Patients in the Construction of a Childbearing-Friendly Society"
Recently, under the guidance of the China Population Association and hosted by the China Medical and Health Development Foundation, with the协办of the Beijing Health City Construction Promotion Association, a research report was organized with experts in demography, oncology, epidemiology, and reproductive science on the topic of "Protection of Fertility for Cancer Patients under the Construction of a Childbirth-Friendly Society." Dr. Pan Ke from Asieris Pharmaceuticals was invited to participate in the dialogue exchange.
· Ms. Xu Ying, Chief Business Officer, was invited to attend2025 China International Fair for Trade in Services
On September 14, the "Forum on Innovative Advances in Cancer Treatment and New Trends in Drug Development" of the 2025 China International Fair for Trade in Services was successfully held. The forum brought together experts and scholars from the field of cancer prevention and treatment in China and abroad to engage in in-depth discussions on innovative technologies in cancer treatment and new trends in drug development. Ms. Ying Xu, Chief Business Officer of Asia-Pacific Pharma, was invited to participate and share insights.
· Ounalin® Multi-City First Prescription Launched, Enhancing Accessibility of Late-Stage Breast Cancer Treatment
· Ms. Xu Ying, Chief Business Officer, was invited to attend2025 China International Fair for Trade in Services
On September 14, the "Forum on Innovative Advances in Cancer Treatment and New Trends in Drug Development" of the 2025 China International Fair for Trade in Services was successfully held. The forum brought together experts and scholars from the field of cancer prevention and treatment in China and abroad to engage in in-depth discussions on innovative technologies in cancer treatment and new trends in drug development. Ms. Ying Xu, Chief Business Officer of Asia-Pacific Pharma, was invited to participate and share insights.
· Ounalin® Multi-City First Prescription Launched, Enhancing Accessibility of Late-Stage Breast Cancer Treatment
On September 25, Asieris Pharmaceuticals announced that its product Onarlin® (a novel microtubule inhibitor, eribulin mesylate injection, hereinafter referred to as "eribulin") for the treatment of advanced breast cancer was first prescribed in multiple cities including Yancheng, Xuzhou, Xi'an, Chengdu, and Harbin.
03
Approval Status of New Drugs and Devices from Invested Companies
Century K-Tai
· Meishi Season®️ OK Lens Glorious Launch
Century K-Tai
· Meishi Season®️ OK Lens Glorious Launch
On September 5, at the Century KANGTAI booth (B106) of the 29th Chinese Ophthalmological Society Congress (CCOS 2025), a launch ceremony themed "Shaping the Future" was grandly held. The Meishi Ji® OK Lens, a rigid gas-permeable corneal reshaping lens independently developed by Century KANGTAI based on artificial intelligence optimization algorithms, has been honorably launched!
Noliving Biotech
· NMPA Approves Nilotinib Bio IABP for Class III Medical Device Registration
Recently, Nuoling Biotech's IABP has been approved for NMPA Class III medical device registration. In the future, Nuoling Biotech will continue to safeguard lives with exceptional dedication.
SMAVEW Biotech
· Successfully Approved for the "2025 Lin-gang Special Area Patent Navigation Project"
Recently, the Market Supervision Administration of Lingang New Area organized the application process for the 2025 Patent Navigation Project. After multiple rounds of independent applications by innovative entities, material review, and expert evaluation, Biaoxin Biotech successfully obtained approval for the "2025 Lingang New Area Patent Navigation Project."
Ruisipuli
· Budesonide/Formoterol Powder Inhaler (II) Clinically Approved
Noliving Biotech
· NMPA Approves Nilotinib Bio IABP for Class III Medical Device Registration
Noliving Biotech
· NMPA Approves Nilotinib Bio IABP for Class III Medical Device Registration
Recently, Nuoling Biotech's IABP has been approved for NMPA Class III medical device registration. In the future, Nuoling Biotech will continue to safeguard lives with exceptional dedication.
SMAVEW Biotech
· Successfully Approved for the "2025 Lin-gang Special Area Patent Navigation Project"
SMAVEW Biotech
· Successfully Approved for the "2025 Lin-gang Special Area Patent Navigation Project"
SMAVEW Biotech
· Successfully Approved for the "2025 Lin-gang Special Area Patent Navigation Project"
Recently, the Market Supervision Administration of Lingang New Area organized the application process for the 2025 Patent Navigation Project. After multiple rounds of independent applications by innovative entities, material review, and expert evaluation, Biaoxin Biotech successfully obtained approval for the "2025 Lingang New Area Patent Navigation Project."
Ruisipuli
· Budesonide/Formoterol Powder Inhaler (II) Clinically Approved
Ruisipuli
· Budesonide/Formoterol Powder Inhaler (II) Clinically Approved
Ruisipuli
· Budesonide/Formoterol Powder Inhaler (II) Clinically Approved
Recently, Budesonide/Formoterol Fumarate Inhalation Powder (II), developed by Zhuhai Risi Pulmic Pharmtech Co., Ltd., a wholly-owned subsidiary of Shenzhen Risi Pulmic Pharmaceutical Co., Ltd. (Company pipeline code: RSG0201), has received the Phase III clinical trial approval from the National Medical Products Administration.
04
Honors of Invested Enterprises
Selected for [IFCC]Official Website Reagent Analysis Performance Reference Table and Anti-Interference Performance Table (v082025)
· Promed Technology hs-cTnI STAT, hs-cTnT STAT, NT-proBNP, and NT-proBNP STAT
SelectedBeijing "New Technologies, New Products, and New Services" Certification
· Huahao Zhongtian "Utidelone Capsules"
Selected for [CCI】Top Ten Innovative Enterprises
· Northcore Life
Selected by [China Fund News】2025 China Listed Company Elite Awards - Outstanding Board Secretary
· MicroCore Bio-Seagull
Selected [ChinaInternational Beauty Expo】2025 SUPER Top 10 Ingredients First
· Healthgen Biotech - Plant-derived Recombinant Human Serum Albumin
Selected【PharmaCube】China's Innovative Drug Decade of Glory - Industry Leading Biotech Companies
·Ascentage Pharma, Harbour BioMed, Chipscreen Biosciences
Selected[ChinaMedical Leaderboard2025 China Biomedical Science and Technology Innovation Value Ranking-Top 10 Best Cases of Technology Achievement Transformation
· HBM Multi-Specific Antibody Platform Project
Selected[ChinaMedical Leaderboard2025 China Biomedical Science and Technology Innovation Value Ranking - Top 10 Most Growth-Oriented Biopharmaceutical Enterprises
· Quanxin Biotech
EntrySelect [Huayi List】Top 10 Most Growth-Oriented Small Molecule Innovative Drug Companies in China's Biomedical Science and Technology Innovation Value Ranking 2025
·Xuanzhu Biotech
EntrySelect【Stanford University, USA & Elsevier】2025 Annual and Lifetime Impact "Top 2% Global Leading Scientists"
· HaploX - Dr. Shi Fu Chen
EntrySelect【HuaMedical Leaderboard2025 China Biomedical Technology InnovationNew Value List-Top 10 Most Promising Cell and Gene Therapy Companies
· Healthgen Biotech
EntrySelect【MicroChain】Top 100 Future Unicorn Companies in China's AI Overseas Expansion 2025
· Westlake Omics
05
Yifeng Honor
✦
Recommended Reading
✦
Bokang Vision Cloud Hong Kong Main Board IPO
SMAVEW Hong Kong Main Board IPO
Quanxin Biotech Hong Kong Main Board IPO
Against the Current, Moving Forward with Time
3D Medicines Hong Kong Main Board IPO
Healthgen Biotech's STAR Market IPO
A Decade of Sharpening the Sword - When Drawn, It Must Shine
Athena Med's STAR Market IPO
Looking forward to your
Share
Like
In view
✦
Recommended Reading
✦
Bokang Vision Cloud Hong Kong Main Board IPO
Bokang Vision Cloud Hong Kong Main Board IPO
SMAVEW Hong Kong Main Board IPO
Quanxin Biotech Hong Kong Main Board IPO
Against the Current, Moving Forward with Time
3D Medicines Hong Kong Main Board IPO
Healthgen Biotech's STAR Market IPO
A Decade of Sharpening the Sword - When Drawn, It Must Shine
Athena Med's STAR Market IPO
Looking forward to your
Share
Like
In view